Drug Discovery

Supporting CROs and CMOs in the development of new generation therapeutics

Drug Discovery

Supporting CROs and CMOs in the development of new generation therapeutics

Gene and cell therapy development offers huge potential to transform the treatment of a range of serious diseases, from cancer and cystic fibrosis to heart disease and diabetes. As a relatively young field of science, new discoveries emerge frequently, with rapid refinement of pioneering viral vector gene therapies, gene therapy trials, and companion diagnostics.

With strong competition and a dynamic regulatory environment, drug discovery organisations developing their laboratory facilities need to retain ultimate flexibility whilst complying with GLP or GMP standards. Premium quality equipment that will support high precision work and provide ultra-clean air environments is an essential part of the lab toolkit.

Clean air for CROs

We understand the requirements of Contract Research Organisations (CROs), often aiming to become or operating as spin-outs from universities or large pharma businesses. Research is mostly with product candidates at the pre-clinical to early clinical stages of drug development and might incorporate work with viral vectors, CAR-T cell therapies or gene expression assays.

However your facility is configured, from GMP cleanroom suites, to fill and finish suites or QC laboratories, we can provide bespoke positive pressure isolators, microbiological safety cabinets and fume cupboards for:

Tissue culture and cell engineering

Process R&D

QC chemistry and microbiology

Analytical services and clinical analysis

Our containment solutions meet the highest quality standards and offer ergonomic designs for user comfort and protection.

High containment for CMOs

For contract manufacturing organisations (CMOs) specialising in GMP manufacture and sterile fill-finish of vials for clinical trials or low volume commercial supply, we offer a wide range of containment solutions.

Our wide portfolio of isolators are designed to protect users and product when filling biological pharmaceutical products such as antibodies, proteins, peptides, DNAs, RNAs, ADCs and cytotoxic, cytostatic and high potent APIs.

What’s more, despite the niche nature of many of these therapeutics, our solutions can support continuous as well as batch processing, as well as the rapid change out between high potent and non-potent compounds.